QQ客服 官方微博 反馈留言

	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
	Zhang, Pin; Sun, Tao; Zhang, Qingyuan; Yuan, Zhongyu; Jiang, Zefei; Wang, Xiao Jia; Cui, Shude; Teng, Yuee; Hu, Xi-Chun; Yang, Junlan
	2017
卷号	18期号:3页码:371-383
ISSN号	1470-2045
DOI	10.1016/S1470-2045(17)30088-8
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6368318
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhang, Pin,Sun, Tao,Zhang, Qingyuan,et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial[J],2017,18(3):371-383.
APA	Zhang, Pin.,Sun, Tao.,Zhang, Qingyuan.,Yuan, Zhongyu.,Jiang, Zefei.,...&Xu, Binghe.(2017).Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.,18(3),371-383.
MLA	Zhang, Pin,et al."Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial".18.3(2017):371-383.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。